SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 6 analyzed stories

Lilly and Hims & Hers expand access to FDA-approved Lilly medicines

Eli Lilly and Hims & Hers announced an agreement to offer eligible patients prescribed Zepbound or Foundayo through Hims & Hers’ platform the same self-pay prices available to other patients. The platform will handle consultation and prescription steps and arrange home delivery; monthly prices start at $149 for Foundayo and $299 for Zepbound.

Published:

Updated:

What happened

Hims & Hers and Eli Lilly announced an agreement to offer eligible patients Lilly’s Zepbound injections and Foundayo pills through the Hims & Hers platform. A provider must prescribe the medicine. Monthly self-pay prices start at $299 for Zepbound and $149 for Foundayo, and Hims will not offer compounded copies of Lilly’s medicines.

Global impact / market context

The agreement gives eligible patients another way to consult a provider and receive prescribed Lilly medicines at the same self-pay prices available elsewhere, with home delivery. It also means Hims will not offer compounded copies of Lilly’s GLP-1 medicines, changing what it offers in this area.

What to watch

  1. Check which patients are eligible, because the agreement does not make the medicines available to everyone.
  2. Check whether a provider prescribes the medicines, because access depends on a provider deciding they are appropriate.
  3. Check whether the stated starting prices and home delivery remain available, because they shape what eligible patients can access and pay.

Affected assets

  • Eli Lilly and Company
  • Hims & Hers Health, Inc.

Evidence